Amanda Handley
Research Subjects
Amanda Handley has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Julie E. Bines
Enteric Diseases Group, Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia
2 shared publications - Anell Meyer
Enteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia
1 shared publication - Ann Turner
Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UK
1 shared publication - Ashley Mpakiza
Malawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, Malawi
1 shared publication - Benjamin Morgan
Enteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia
1 shared publication Celeste M. Donato
The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria, Australia; Enteric Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 266, 114572
Environmental surveillance for Salmonella Typhi to detect the typhoid burden in Yogyakarta, Indonesia
- 1 April 2025
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 266, 114572
Open AccessEnvironmental surveillance for Salmonella Typhi to detect the typhoid burden in Yogyakarta, Indonesia
- Open Access
Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi
High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (p < 0.005) and 3 (p < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease.
Open AccessRotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi
High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (p < 0.005) and 3 (p < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease.